2024-11-01 2025-10-31 false Capium Accounts Production 1.1 14415580 2024-11-01 2025-10-31 14415580 bus:AbridgedAccounts 2024-11-01 2025-10-31 14415580 bus:FRS102 2024-11-01 2025-10-31 14415580 bus:AuditExemptWithAccountantsReport 2024-11-01 2025-10-31 14415580 bus:SmallCompaniesRegimeForAccounts 2024-11-01 2025-10-31 14415580 bus:PrivateLimitedCompanyLtd 2024-11-01 2025-10-31 14415580 2024-11-01 2025-10-31 14415580 2025-10-31 14415580 bus:RegisteredOffice 2024-11-01 2025-10-31 14415580 core:WithinOneYear 2025-10-31 14415580 core:AfterOneYear 2025-10-31 14415580 1 2024-11-01 2025-10-31 14415580 bus:Director1 2024-11-01 2025-10-31 14415580 bus:Director1 2025-10-31 14415580 bus:Director1 2023-11-01 2024-10-31 14415580 2023-11-01 14415580 bus:LeadAgentIfApplicable 2024-11-01 2025-10-31 14415580 2023-11-01 2024-10-31 14415580 2024-10-31 14415580 core:WithinOneYear 2024-10-31 14415580 core:AfterOneYear 2024-10-31 14415580 bus:EntityAccountantsOrAuditors 2023-11-01 2024-10-31 14415580 bus:OrdinaryShareClass1 2024-11-01 2025-10-31 14415580 bus:OrdinaryShareClass1 2025-10-31 14415580 bus:OrdinaryShareClass1 2023-11-01 2024-10-31 14415580 bus:OrdinaryShareClass1 2024-10-31 14415580 core:CostValuation core:Non-currentFinancialInstruments 2025-10-31 14415580 core:CostValuation core:Non-currentFinancialInstruments 2024-10-31 14415580 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2025-10-31 14415580 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2025-10-31 14415580 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-10-31 14415580 core:Non-currentFinancialInstruments 2025-10-31 14415580 core:Non-currentFinancialInstruments 2024-10-31 14415580 core:ShareCapital 2025-10-31 14415580 core:ShareCapital 2024-10-31 14415580 core:RetainedEarningsAccumulatedLosses 2025-10-31 14415580 core:RetainedEarningsAccumulatedLosses 2024-10-31 14415580 dpl:Item1 2024-11-01 14415580 dpl:Item1 2025-10-31 14415580 dpl:Item1 2023-11-01 14415580 dpl:Item1 2024-10-31 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 14415580
England and Wales

 

 

 

CHITOSHIBA MEDICS LTD



Abridged Accounts
 


Period of accounts

Start date: 01 November 2024

End date: 31 October 2025
Accountant’s report
You consider that the company is exempt from an audit for the year ended 31 October 2025 . You have acknowledged, on the balance sheet, your responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. These responsibilities include preparing accounts that give a true and fair view of the state of affairs of the company at the end of the financial year and of its profit or loss for the financial year.
In accordance with your instructions, we have prepared the accounts which comprise the Profit and Loss Account, the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes from the accounting records of the company and on the basis of information and explanations you have given to us.
We have not carried out an audit or any other review, and consequently we do not express any opinion on these accounts.
NEWINTON ACCOUNTANCY LTD
31 October 2025



....................................................

NEWINTON ACCOUNTANCY LTD




22 July 2026
1
 
 
Notes
 
2025
£
  2024
£
Fixed assets      
Investments 3 48,000   
48,000   
Current assets      
Debtors 12,767    3 
Cash at bank and in hand 12,467    52,022 
25,234    52,025 
Creditors: amount falling due within one year (13,607)   (21,703)
Net current assets 11,627    30,322 
 
Total assets less current liabilities 59,627    30,322 
Net assets 59,627    30,322 
 

Capital and reserves
     
Called up share capital 4 1    1 
Profit and loss account 59,626    30,321 
Shareholders' funds 59,627    30,322 
 


For the year ended 31 October 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:
  1. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476.
  2. The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with section 444(2A).
The financial statements were approved by the director on 22 July 2026 and were signed by:


-------------------------------
Chinyere Iloba
Director
2
General Information
CHITOSHIBA MEDICS LTD is a private company, limited by shares, registered in England and Wales, registration number 14415580, registration address 34 WILKS ROAD, DARTFORD ENGLAND, DA2 6FT.

The presentation currency is £ sterling.
1.

Accounting policies

Significant accounting policies
Statement of compliance
These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.
Basis of preparation
The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies.
The financial statements are prepared in sterling which is the functional currency of the company.
Turnover
Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts.
2.

Average number of employees

Average number of employees during the year was 2 (2024 : 0).
3.

Investments

Cost Other investments other than loans   Total
  £   £
At 01 November 2024  
Additions 48,000    48,000 
Disposals  
At 31 October 2025 48,000    48,000 

4.

Share Capital

Allotted, called up and fully paid
2025
£
  2024
£
1 Class A share of £1.00 each  
 

3